Skip to content

Search

Why timing matters: How tumours respond to immunotherapy treatments over time

Researchers have identified key differences between cancers that respond to immunotherapy and those that do not.

Researchers narrow down field of new treatments for most common childhood brain cancer

Cancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.

Biobank funding supports valuable research resources

Four The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.

The Kids Cancer Researcher wins prestigious Cancer Council WA award

The Kids Research Institute Australia cancer researcher, Dr Jason Waithman, has been named Cancer Council WA’s 2021 Cancer Researcher of the Year.

Funding partnership to uncover new brain cancer treatments for kids

The Robert Connor Dawes Foundation has joined forces with the Ethan Davies Fellowship to co-fund a The Kids Research Institute Australia initiative aimed at uncovering new treatments for aggressive childhood brain tumours.

Meet the The Kids Sarcoma Translational Research Team

This year for Childhood Cancer Awareness Month, we got to know the sarcoma research team at Telethon Kids.

Determining risk features for medulloblastoma in the molecular era

Nick Gottardo MBChB FRACP PhD Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome.

Incidence and survival for childhood central nervous system tumours in Australia, 1983–2016

To investigate incidence and survival of childhood tumours of the central nervous system (CNS) by histological subtype, tumour behaviour and tumour grade. Methods: National, population-based data on all children under 15 years old diagnosed with a CNS tumour between 1983 and 2016 were sourced from the Australian Childhood Cancer Registry. Incidence rate trends were calculated using Joinpoint regression.

Viridans Group Streptococci in Pediatric Leukemia and Stem Cell Transplant: Review of a Risk-stratified Guideline for Empiric Vancomycin in Febrile Neutropenia

Viridans group streptococci (VGS) are an important cause of sepsis in immunosuppressed children. We reviewed the effectiveness of risk-stratified addition of vancomycin to empiric febrile neutropenia therapy among 107 children with leukemia or undergoing an allogeneic transplant.